Home Barinthus Biotherapeutics

Barinthus Biotherapeutics

In operation
IPO
Developer of Novel T Cell Immunotherapy
Basic
Enterprise Profile

Basic Information

Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a clinical-stage biopharmaceutical company focused on developing novel T-cell immunotherapies to harness the immune system to combat chronic infectious diseases, autoimmune disorders, and cancer.
Barinthus Biotherapeutics plc
Oxford,England,United Kingdom
more than 500 people
January 01, 2016
https://www.barinthusbio.com/
pippa@vaccitech.co.uk

Enterprise Profile

Industrial Sector
New Drug Development Immune Cell Therapy Vaccine Formulation Production
Technology
Immunological Techniques
Concept
Infectious Diseases Department Infectious Diseases Immune System Diseases Therapeutic Products Prostate Cancer
Application Scenarios
Biologics Innovative Drugs Traditional Vaccines (Biological Products for Prevention)